Glucokinase gene promoter -30G>A polymorphism: a cross-sectional association study with obesity, diabetes Mellitus, hyperlipidemia, hypertension and metabolic syndrome in an Iranian hospital

Abstract

OBJECTIVE: A -30G>A single nucleotide polymorphism in the promoter region of the glucokinase gene has been previously associated with obesity, insulin resistance and diabetes. The present study aimed to evaluate the association of this polymorphism with obesity and its comorbidities in a population from Northeast Iran. METHODS: Five hundred and forty-two subjects aged 18 to 65 years were included in the study and divided into normal (BMI<25, n=220), overweight (25<BMI<30, n=135) and obese (BMI>30, n=187) groups. All subjects were genotyped for the -30G>A polymorphism using the polymerase chain reaction-restriction fragment length polymorphism technique. RESULTS: The genotypes and allele frequencies of the three groups did not differ significantly (p>0.05). When the study population was categorized according to diabetes mellitus, hyperlipidemia, hypertension and metabolic syndrome status, no significant difference in -30G>A genotypes and alleles was found between the subgroups with and without these disorders (p>0.05), apart from a significantly higher frequency of the G allele in the hyperlipidemic vs. non-hyperlipidemic subgroup (p<0.05). CONCLUSION: The findings of the present study do not support an association between the -30G>A polymorphism and high body mass index in the Iranian population.

Association between Genetic Variants and Diabetes Mellitus in Iranian Populations: A Systematic Review of Observational Studies

“…In contrast to above variants, CTLA4 (+49A/G polymorphism), HNF-1 α (Ala98Val polymorphism), GLP-1R (glucagon-like peptid 1 receptor) (Thr149Met polymorohism), SLC30A8 (Arg325Trp polymorphism), GSTP1 (Ile105Val polymorphism), glucokinase (−30G/A polymorphism), SDF-1 β (stromal derived factor -1 β ) (G801A polymorphism), ApoE (apolipoprotein E), ENPP1 (ectoenzyme nucleotide pyrophosphate phosphodiesterase 1) (K121Q polymorphism), SUMO4 (small ubiquitin-like modifier 4) Met55Val polymorphism), MTHFR (C677T polymorphism), UCP2 (uncoupling protein 2) (−866G/A polymorphism), 5HTTLPR, IL-4 (−590C/T polymorphism), IFN- γ (interferon γ ) (+874T/A polymorphism), CCR5 (C-C chemokine receptor type 5) ( δ 32mutation), HFE (hemochromatosis gene) (H63D, C282Y, PTPN1 (protein tyrosin Phosphatase 1B)/−51delA, −451A>G, −467T>C, −1023C>A, −1045G>A, −1286 3 bp del ACA, −1291 9 bp del CTAGACTAA polymorphisms) were not significantly associated with T2DM [ 22 , 42 , 46 , 50 – 52 , 54 , 59 – 63 , 66 , 67 , 71 , 74 ].…”